What is Cryosa?
Cryosa is dedicated to advancing the treatment of sleep apnea through the development of minimally invasive devices. Unlike traditional methods that often require daily patient compliance, Cryosa's innovative solutions aim to provide a more convenient and effective therapeutic experience. The company's focus on non-intrusive technology positions it as a key player in the evolving landscape of respiratory care.
How much funding has Cryosa raised?
Cryosa has raised a total of $35.7M across 3 funding rounds:
Series A
$8.3M
Series B
$21.5M
Private Equity
$6M
Series A (2020): $8.3M with participation from Santé Ventures and HOYA Corporation
Series B (2021): $21.5M led by Santé Ventures, HOYA, and Solas BioVentures
Private Equity (2025): $6M, investors not publicly disclosed
Key Investors in Cryosa
Santé Ventures
Santé Ventures is a venture capital firm specializing in innovative healthcare and technology companies, with a focus on Biotech, Medtech, and Healthtech sectors. They invest in visionary entrepreneurs aiming to enhance patient health outcomes.
HOYA
HOYA is a Japanese multinational company specializing in optics and high-tech products. Their investment in Cryosa suggests an interest in medical device innovation and potentially synergistic technologies within the healthcare sector.
Solas BioVentures
Solas BioVentures is a venture capital firm focused on early-stage life sciences investments, including biopharmaceuticals, medical devices, and digital health. They support innovators aiming to transform patient care.
What's next for Cryosa?
The recent major strategic investment signals a pivotal growth phase for Cryosa. This capital infusion is expected to accelerate product development, scale manufacturing capabilities, and expand market reach. With a clear focus on addressing a significant unmet need in sleep disorder treatment, Cryosa is poised to leverage this financing to further its mission and solidify its position in the medtech industry. Future endeavors will likely involve clinical validation and broader commercialization efforts.
See full Cryosa company page
